Psychosocial issues and outcomes in maternal PKU

Molecular Genetics and Metabolism

Volumn 99, Issue SUPPL., 2010, Pages

  Koch, Richard ^a   Trefz, Friedrich ^b   Waisbren, Susan ^c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Klinikum am Steinenberg   (Germany)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Maternal phenylketonuria; Phenylketonuria; Pregnancy; Sapropterin

Indexed keywords

PHENYLALANINE; PHENYLALANINE AMMONIA LYASE; SAPROPTERIN; TYROSINE;

ARTICLE; BEHAVIOR DISORDER; BIRTH DEFECT; COGNITIVE DEFECT; CONGENITAL HEART DISEASE; DEMOGRAPHY; DEVELOPMENTAL DISORDER; DIET RESTRICTION; DISEASE SEVERITY; ENZYME THERAPY; FETAL ALCOHOL SYNDROME; FETUS DEVELOPMENT; FETUS DISEASE; FINANCIAL MANAGEMENT; HEALTH CARE ACCESS; HEALTH EDUCATION; HOME ENVIRONMENT; HUMAN; INTELLIGENCE QUOTIENT; LOW BIRTH WEIGHT; MATERNAL WELFARE; MENTAL DISEASE; METABOLIC REGULATION; MICROCEPHALY; NONHUMAN; PATIENT COMPLIANCE; PATIENT COUNSELING; PHENYLKETONURIA; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REIMBURSEMENT; RISK FACTOR; SOCIAL PSYCHOLOGY; SOCIAL SUPPORT; TERATOGENICITY; UNITED STATES; UNPLANNED PREGNANCY;

EID: 72249110869     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2009.10.014     Document Type: Article

References (63)

1. Hanley W.B., Clarke J.T.R., and Schoonheyt W. Maternal phenylketonuria (PKU): a review. Clin. Biochem. 20 (1987) 149-156
2. American Academy of Pediatrics Committee on Genetics. Policy statement: maternal phenylketonuria. Pediatrics 122 (2008) 445-449
3. Levy H. Historical background for the maternal PKU syndrome. Pediatrics 112 (2003) 1516-1518
4. Dent C.E. The relation of biochemical abnormality to the development of mental defect in phenylketonuria. Etiologic Factors in Mental Retardation: Report of the 23rd Ross Pediatric Research Conference (1957), Ross Laboratories, Columbus, OH 28-33
5. Lenke R.R., and Levy H. Maternal phenylketonuria and hyperphenylalaninemia: an international survey of the outcome of treated and untreated pregnancies. N. Engl. J. Med. 303 (1980) 1202-1208
6. Antshel K.M., and Waisbren S.E. Developmental timing of exposure to elevated levels of phenylalanine is associated with ADHD symptom expression. J. Abnorm. Child. Psychol. 31 (2003) 565-574
7. Antshel K.M., and Waisbren S.E. Timing is everything: executive functions in children exposed to elevated levels of phenylalanine. Neuropsychology 17 (2003) 458-468
8. Medical Research Council Working Party on Phenylketonuria. Recommendations on the dietary management of phenylketonuria. Arch. Dis. Child. 68 (1993) 426-427
9. Lee P.L., Ridout D., Walter J.H., and Cockburn F. Maternal phenylketonuria: report from the United Kingdom Registry 1978-97. Arch. Dis. Child. 90 (2005) 143-146
10. Koch R., de la Cruz F., and Azen C. The maternal phenylketonuria collaborative study: new developments and the need for new strategies. Pediatrics 112 (2003) 1513-1587
11. Burgard P., Bremer H.J., Buhrdel P., Clemens P.C., Monch E., Przyrembel K., et al. Rationale for the German recommendations for phenylalanine level control in phenylketonuria 1997. Eur. J. Pediatr. 158 (1999) 46-54
12. Koch R., Hanley W., Levy H., Matalon K., Matalon R., Rouse B., et al. The maternal phenylketonuria international study: 1984-2002. Pediatrics 112 (2003) 1523-1529
13. Ng T.-W., Rae A., Wright H., Gurry D., and Wray J. Maternal phenylketonuria in Western Australia: pregnancy outcomes and developmental outcomes in the offspring. J. Pediatr. Child Health 39 (2003) 358-363
14. Maillot F., Lilburn M., Baudin J., Morley D.W., and Lee P.J. Factors influencing outcomes in the offspring of mothers with phenylketonuria during pregnancy: the importance of variation in maternal blood phenylalanine. Am. J. Clin. Nutr. 88 (2008) 700-705
15. Koch R., and de la Cruz F. Preface. Pediatrics 112 (2003) 1513
16. Waisbren S.E., and Azen C. Cognitive and behavioral development in maternal phenylketonuria offspring. Pediatrics 112 (2003) 1544-1547
17. Totsika V., and Sylva K. The home observation for measurement of the environment revisited. Child. Adolesc. Ment. Health 9 (2004) 25-35
18. Matalon K.M., Acosta P., Azen C., and Matalon R. Congenital heart disease in maternal phenylketonuria: effects of blood phenylalanine and nutrient intake. Ment. Retard. Ment. Disabil. Res. Rev. 5 (1999) 122-124
19. Matalon K.M., Platt L.D., Acosta P., Azen C., and Walla C.A. Nutrient intake and congenital heart defects in maternal phenylketonuria. Am. J. Obstet. Gynecol. 187 (2002) 441-444
20. Matalon K.M., Acosta P.B., and Azen C. Role of nutrition in pregnancy with phenylketonuria and birth defects. Pediatrics 112 (2003) 1534-1536
21. Acosta P.B., Matalon K., Castiglioni L., Rohr F.J., Wenz E., Austin V., et al. Intake of major nutrients by women in the Maternal Phenylketonuria (MPKU) study and effects on plasma phenylalanine concentrations. Am. J. Clin. Nutr. 73 (2001) 792-796
22. Blau N. Maternal PKU. In: Blau N. (Ed). PKU and BH4: Advances in Phenylketonuria and Tetrahydrobiopterin (2006), SPS Verlagsgesellschaft, Heilbronn 261-276
23. Rohr F.J., Lobbreght D., and Levy H.L. Tyrosine supplementation in the treatment of maternal phenylketonuria. Am. J. Clin. Nutr. 67 (1998) 473-476
24. van Spronsen F.J., Smit P.G.A., and Koch R. Phenylketonuria: tyrosine beyond the phenylalanine-restricted diet. J. Inherit. Metab. Dis. 24 (2001) 1-4
25. Guttler F., Azen C., Guldberg P., Romstad A., Hanley W.B., Levy H.L., et al. Impact of the phenylalanine hydroxylase gene on maternal phenylketonuria outcome. Pediatrics 112 (2003) 1530-1533
26. Clarke J.T.R. The maternal phenylketonuria project: a summary of progress and challenges for the future. Pediatrics 112 (2003) 1584-1587
27. Widaman K.F., and Azen C. Relation of prenatal phenylalanine exposure to infant and childhood cognitive outcomes: results from the International Maternal PKU Collaborative Study. Pediatrics 112 (2003) 1537-1543
28. Lee P.J., Lilburn M., and Baudin J. Maternal phenylketonuria: experiences from the United Kingdom. Pediatrics 112 (2003) 1553-1556
29. Platt L.D., Koch R., Hanley W.B., Levy H.L., Matalon R., Rouse B., et al. The international study of pregnancy outcome in women with maternal phenylketonuria: report of a 12-year study. Am. J. Obstet. Gynecol. 182 (2000) 326-333
30. Brown A.S., Fernhoff P.M., Waisbren S.E., Frazier D.M., Singh R., Rohr F., et al. Barriers to successful dietary control among pregnant women with phenylketonuria. Genet. Med. 4 (2002) 84-89
31. Rohr F., Munier A., Sullivan D., Bailey I., Gennaccaro M., Levy H., et al. The Resource Mothers Study of maternal phenylketonuria: preliminary findings. J. Inherit. Metab. Dis. 27 (2004) 145-155
32. Cipcic-Schmidt S., Trefz F.K., Fünders B., Seidlitz G., and Ullrich K. German maternal PKU study. Eur. J. Pediatr. 155 (1996) S173-S176
33. Waisbren S.E., Shiloh S., St. James P., and Levy H.L. Psychosocial factors in maternal phenylketonuria: prevention of unplanned pregnancies. Am. J. Public Health 81 (1991) 299-304
34. Brenton D.P., and Lilburn M. Maternal phenylketonuria: a study from the United Kingdom. Eur. J. Pediatr. 155 (1996) S177-S180
35. St. James P.S., Shapiro E., and Waisbren S.E. The Resource Mothers Program for phenylketonuria. Am. J. Public Health 89 (1999) 762-764
36. Waisbren S.E., Hamilton B.D., St. James P.J., Shiloh S., and Levy H.L. Psychosocial factors in maternal phenylketonuria: women's adherence to medical recommendations. Am. J. Public Health 85 (1995) 1636-1641
37. Shaw-Smith C., Hogg S.L., Reading R., Calvin J., and Trump D. Learning and behavioral difficulties but not microcephaly in three brothers resulting from undiagnosed maternal phenylketonuria. Child Care Health Dev. 30 (2004) 551-555
38. Lipson A., Beuhler B., Bartley J., Walsh D., Yu J., O'Halloran M., et al. Maternal hyperphenylalaninemia fetal effects. J. Pediatr. 104 (1984) 216-220
39. Levy H.L., and Ghavami M. Maternal phenylketonuria: a metabolic teratogen. Teratology 53 (1996) 176-184
40. Waisbren S.E. Developmental and neuropsychological outcome in children born to mothers with phenylketonuria. Ment. Retard. Ment. Disabil. Res. Rev. 5 (1999) 125-131
41. Centers for Disease Control. Barriers to dietary control among pregnant women with phenylketonuria - United States, 1998-2000. MMWR Morb. Mortal. Wkly. Rep. 51 (2002) 117-120
42. Waisbren S.E. Predictors of intelligence quotient and intelligence quotient change in persons treated for phenylketonuria early in life. Pediatrics 79 (1987) 351-355
43. Waisbren S.E., and Zaff J. Personality disorder in young women with treated phenylketonuria. J. Inherit. Metab. Dis. 17 (1994) 584-592
44. Levy H.L., and Waisbren S.E. PKU in adolescents: rationale and psychosocial factors in diet continuation. Acta Paediatr. Suppl. 407 (1994) 92-97
45. Sheard N.F. Importance of diet in maternal phenylketonuria. Nutr. Rev. 58 (2000) 236-239
46. Waisbren S.E. Outcome at age 4 years in offspring of women with maternal phenylketonuria: the Maternal PKU Collaborative Study. JAMA 283 (2000) 756-762
47. Waisbren S.E., Chang P., Levy H.L., Shifrin H., Allred E., Azen C., et al. Neonatal neurological assessment of offspring in maternal phenylketonuria. J. Inherit. Metab. Dis. 21 (1998) 39-48
48. van Spronsen F.J., Ahring K.K., and Gizewska M. PKU - what is the daily practice in various centres in Europe?. J. Inherit. Metab. Dis. 32 (2009) 58-64
49. National Institutes of Health, Phenylketonuria: screening and management. , 2009 (accessed 20.07.09).
50. The National Society for Phenylketonuria (United Kingdom) Limited, Management of PKU. , 2009 (accessed 24.09.09).
51. Trefz F.K., Ullrich K., Cipcic-Schmidt S., Fünders-Bücker B., van Teeffelen-Heithoff A., and Przyrembel H. Prophylaxe und Behandlung der maternalen Phenylketonurie (MPKU) Stellungnahme der Arbeitsgemeinschaft für Pädiatrische Stoffwechselstörungen. Monatsschr Kinderheilkd 143 (1995) 898-899
52. Sarkissian C.N., Gamez A., Wang L., Charbonneau M., Fitzpatrick P., Lemontt J.F., et al. Preclinical evaluation of multiple species of PEGylated recombinant phenylalanine ammonia lyase for the treatment of phenylketonuria. Proc. Natl. Acad. Sci. USA 105 (2008) 20894-20899
53. Kuvan [package insert] Novato (CA): BioMarin Pharmaceutical, Inc., 2007.
54. Trefz F.K., and Blau N. Potential role of tetrahydrobiopterin in the treatment of maternal phenylketonuria. Pediatrics 112 (2003) 1566-1569
55. Koch R., Mosely K., and Guttler F. Tetrahydrobiopterin and PKU. Mol. Genet. Metab. 86 (2005) S139-S141
56. Koch R. Maternal phenylketonuria and tetrahydrobiopterin. Pediatrics 122 (2008) 1367-1368
57. Koch R., and Mosely K. Maternal phenylketonuria and tetrahydrobiopterin. Mol. Genet. Metab. 98 (2009) 37
58. 4) and Maternal phenylketonuria two case studies. ICAN 1 (2009) 262-266
59. Cunningham A., Pridjian G., Smith J., and Andersson H.C. PKU treatment with tetrahydrobiopterin (sapropterin) during pregnancy. Mol. Genet. Metab. 98 (2009) 24 (Poster 187)
60. Waisbren S.E., Rokni H., Bailey I., Rohr F., Brown T., and Warner-Rogers J. Social factors and the meaning of food in adherence to medical diets: results of a maternal phenylketonuria summer camp. J. Inherit. Metab. Dis. 20 (1997) 21-27
61. Singh R.H., Kable J.A., Guerrero N.V., Sullivan K.M., and Elsas II L.J. Impact of a camp experience on phenylalanine levels, knowledge, attitudes, and health beliefs relevant to nutrition management of phenylketonuria in adolescent girls. J. Am. Diet. Assoc. 100 (2000) 797-803
62. Guthrie R., and Susi A. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics 32 (1963) 338-343
63. Rouse B., and Azen C. Effect of high maternal blood phenylalanine on offspring congenital anomalies and developmental outcome at ages 4 and 6 years: the importance of strict dietary control preconception and throughout pregnancy. J. Pediatr. 144 (2004) 235-239